Investor Presentaiton
Company overview
Financial review
2022 priorities
Appendix
References
1 GROWTH
Strong Kesimpta®Ⓡ launch continues, outperforming market
CEZ K Kesimpta L
Sales evolution
USD m, % cc
Ex-US
US
99
66
50
147
109
+24%
239
195
Q1/21
Q2/21
Q3/21
Q4/21
Q1/22
Q2/22
Launch acceleration continues
Increasing real-world experience with >20k patients treated WW
US demand +18% QoQ, >3,200 adopters since launch
NBRX +42% YoY vs. US NBRx market -12%1
Strengthening differentiation and benefit/risk profile
New extension phase data: 8/10 patients treated continuously with
KesimptaⓇ had no evidence of disease activity (NEDA-3)²
Fast initiation within 6 days for 80% patients³
77% of patients remain on therapy at 12 months4
See last slide for references WW-worldwide NBRX - New to brand Prescription NEDA - No Evidence of Disease Activity
12 Investor Relations | Q2 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation